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Personalised medicine in general practice as exemplified by management of 
raised cholesterol 
 
With the rollout of the 100,000 genome project, NHS policymakers are working to maximize the 
benefits to patients of Personalised Medicine.  In the USA, this is also termed “Precision Medicine”.  
Many general practitioners consider they already offer “personalised medicine”, recognising that 
“one size does not fit all” and that management requires   patients’ medical histories and 
psychosocial issues are taken into account.  Whilst the field of genomics has been developing for 
many years its clinical value has, to date, largely been in the diagnosis of rare inherited diseases. 
However, genomic information is increasingly offering the potential for transformed healthcare, 
including better prediction of potential disease, earlier and more accurate diagnosis, and prescribing 
tailored to an individual’s likelihood of seeing benefit. Better interrogation of electronic healthcare 
records in Primary Care offers an opportunity to stratify patients into sub-groups for targeted 
management and this is expected to lead to improved efficiency in the Health Service.(1)  An 
alternative way of describing this new approach is “Stratified medicine”, and this is already 
recognised in General Practice, as demonstrated by the asthma and COPD clinical care pathways.(2)   
 
In particular, genomic analysis, taken with the better interpretation of information in electronic 
health records, has the potential to improve the detection and management of common conditions 
earlier in life. This will allow interventions that may prolong healthy life to be started earlier than by 
using the current approach, which is largely dependent on a clinical event occurring before a 
diagnosis is made and an intervention offered. A good example of this is the identification of high 
cholesterol levels in an individual, which is recognised to cause a higher lifetime risk of coronary 
heart disease (CHD). Causes of raised blood cholesterol may be stratified into those due to 
environmental and/or polygenic factors, with  a small proportion of individuals having a single 
genetic defect (i.e. a monogenic cause) , most commonly, a  disease called  familial 
hypercholesterolemia (FH).  FH is an autosomal dominant condition, meaning that, on average 50% 
of the children and siblings of an affected individual will have inherited the same gene mutation. It is 
estimated that around 1:250 of the general population have FH , with a possible 240,000 FH patients 
in the UK, making it one of the most common monogenic disorders and much more common than 
type 1 diabetes.  Compared to those who have a multifactorial cause for elevation of cholesterol 
levels, those with monogenic FH have over a three-fold higher risk of premature CHD and would be 
expected to lose roughly 10 years of healthy life as a consequence.  If treatment (usually with 
statins) is started early enough and cholesterol is well controlled, those with FH can expect to have 
  
the same life expectancy as their unaffected siblings (3).  It is advised this initial management takes 
place under specialist care rather than general practice. In a small proportion of FH patients, where 
on-treatment cholesterol levels remain above recommended targets, treatment with more powerful 
lipid-lowering PCSK9 monoclonal antibodies may also be considered.  Compared to early and 
intensive lipid-lowering statin therapy  for monogenic causes of raised cholesterol, those with a 
polygenic and multifactorial causes can be managed using standard  statin therapy in general 
practice. This is a clear example of how knowing the underlying genetic aetiology of an individual’s 
hypecholesterolaemia will lead to “stratified” medicine approach, which will also focus NHS 
resources on those at highest risk where benefit of intensive lipid lowering therapy will be greatest.  
 
In the recently revised familial hypercholesterolemia NICE guidelines (4) the recommendations 
relevant to primary care are summarised in Box 1, highlighting those that have been amended since 
the 2008 guidelines.(4,5) Taking into account the 99.5th percentile of total cholesterol in the UK 
general population,  it is recommended that all individuals in a General Practice database  aged 
between 16-29 years with a total cholesterol > 7.5mmol/l and all individuals age  30 years and older 
with a total cholesterol over 9.0mmol/l should be assessed for FH. Also, a premature history of CHD 
may indicate the possibility of FH, and GPs are recommended to suspect this possible diagnosis if an 
individual has a first degree relative with evidence of CHD before the age of 60 years. Building on the 
NICE recommendations in the era of “Personalised stratified medicine”, more sophisticated “big data” 
analysis of patient records in general practice computer systems will help predict those individuals 
who are likely to have monogenic FH.(6)   
Further, the current NICE guidelines recognise the critical importance of confirming the diagnosis of 
(monogenic) FH using a genetic (DNA) test and only those found to carry an FH-causing gene mutation, 
on testing, will then be given the diagnosis of FH, while those with the clinical features of FH but no 
mutation are best designated as “polygenic hypercholesterolaemia” (7)  Only those relatives of 
patients  with genetic test-confirmed FH should then be “cascade tested” using the genetic test for 
the specific family FH-causing gene mutation, together with lipid measures to determine appropriate 
advice and therapy options. Recent economic analysis has confirmed that this approach is a highly 
cost effective strategy (8), since 50% of first degree relatives will also have the condition.  Of course 
this will result in many children with FH being identified and the guideline recommends that children 
at risk of FH because of one affected parent, should be offered a genetic test at the earliest 
opportunity, and certainly by the age of 10 years, when treatment with statin should be initiated by a 
healthcare professional with expertise in treating children and young people with FH.  
 
  
Box 1:  Key recommendations from the 2017 NICE guidelines to identify familial 
hypercholesterolemia relevant to General Practice  
1.       Suspect familial hypercholesterolaemia (FH) as a possible diagnosis in adults with:  
 a total cholesterol level greater than 7.5 mmol/l, and/or  
 a personal or family history of premature coronary heart disease (coronary event before 60 
years in an index individual or first-degree relative). [2008, amended 2017]  
2. Systematically search primary care records for people:  
 younger than 30 years old, with a total cholesterol concentration greater than 7.5 mmol/l 
and  
 30 years or older, with a total cholesterol concentration greater than 9.0 mmol/l  
as these are the people who are at highest risk of FH. [new 2017] 
3.  Healthcare professionals should exclude secondary causes of hypercholesterolaemia before a 
diagnosis of FH is considered. [2008] 
4.  To confirm a diagnosis of FH, healthcare professionals should undertake two measurements of 
LDL-Cholesterol concentration because biological and  analytical variability occurs. [2008]  
5.  For people with a personal or family history of premature coronary heart disease offer to 
measure their total cholesterol if not already known. [new 2017]  
6.  Coronary heart disease risk estimation tools should not be used because people with FH are 
already at a high coronary heart disease risk.  [2008, amended 2017] 
7.  Use the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria to make a clinical diagnosis 
of FH in primary care settings. [2008, amended 2017]  
8.  Refer the person to an FH specialist service for genetic testing if they meet the diagnosis criteria 
(see recommendation 7). [new 2017]  
9.  Inform all people who have an identified gene mutation diagnostic of FH that they have the 
diagnosis irrespective of cholesterol level. [2008, amended 2017]  
10.  Offer a high-intensity statin as the initial treatment for all adults with FH and aim for at least a 
50% reduction in LDL-C concentration from the baseline measurement. [new 2017] 
 
 
The updated guideline reinforces the 2008 recommendation that CHD risk estimation tools, such as 
10-year QRISK2 and those based on the Framingham algorithm, should not be used to estimate risk 
in FH patients because people with FH are already at a high lifetime risk of premature CHD.  
However, as a result of the on-going NHS Health Check programme, many individuals will be 
identified with raised cholesterol. These represent a hitherto unrecognised pool of at-risk subjects, a 
significant proportion of whom are likely to carry an FH-causing gene mutation. Further, the risk of 
premature cardiovascular events for those with both monogenic and polygenic FH will be 
exacerbated by traditional risk factors such as smoking and obesity, and the effect of combining 
these risk factors is much greater than the simple sum of their individual contributions. Individuals 
  
identified with FH should be offered similar lifestyle advice and support (e.g. smoking cessation 
measures) as to non-FH subjects to manage these factors. 
  
The choice of lipid lowering therapy for raised cholesterol levels also falls within the domain of 
(personalised) stratified medicine, more commonly described as pharmacogenomics.  A key issue in 
primary care is poor compliance with statin therapy due to perceived musculoskeletal problems. 
Genomic information can indicate those at greatest risk of statin-induced myopathy with specific 
statins, such as simvastatin and rosuvastatin.(9) The evidence base for the impact of genomics on 
therapeutic options in cholesterol management is still emerging. 
 
In the future, to stratify risk and management of patients with raised cholesterol will require 
incorporation of genomic data in Primary Care electronic health records on both monogenic 
disorders conditions and predisposition to more common polygenic variations, combined with better 
access to information on other risk factors for familial hypercholesterolemia and cardiovascular 
disease. The latter will require application of novel data analytic methods, such as advanced 
statistical analysis and machine learning approaches.  Further, effective personalised stratified 
strategies for identification of causes and management of raised cholesterol requires evidence-
based clinical pathways from Primary to Secondary to Tertiary Care.  To improve this referral process 
requires increased awareness of this new taxonomy by both general practitioners and patients. This 
includes embedding these concepts in continuous medical education and revisiting knowledge 
transfer strategies.  An added benefit of systematic interrogation of electronic health records and 
genomic data is equity of access to the appropriate health care, rather than those with greatest 
health literacy at forefront of accessing health services.  This may help break Tudor Hart’s inverse 
care law: better care for all rather than the few. 
 
Conflict of Interest: NQ and SEH were members of the NICE Familial Hypercholesterolaemia 
Guideline Development group (2016-17). SEH was funded by the British Heart Foundation (BHF 
PG08/008) and by the NIHR UCLH BRC. SEH is the Medical Director and minority shareholder of a 
UCL spin-out company called StoreGene, which uses a 20 SNP genetic test, in combination with the 
classical risk factor profile, for estimating an individual’s future risk of CVD.  
 
References 
1. NHS England.  Improving outcomes through personalised medicine. 2016  
https://www.england.nhs.uk/wp-content/uploads/2016/09/improving-outcomes-personalised-
medicine.pdf (Last accessed 2 November 2017) 
  
2. British Thoracic Society/ Scottish Intercollegiate Guidelines Network. British guideline on the 
management of asthma.  A national clinical guideline https://www.brit-thoracic.org.uk/document-
library/clinical-information/asthma/btssign-asthma-guideline-2016/ (Last accessed 2 November 2017) 
 
3. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions 
in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial 
hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008; 29(21):2625-33 
 
4. National Institute for Health and Care Excellence (NICE). Identification and management of familial 
hypercholesterolaemia. NICE clinical guideline addendum CG71. London: NICE, 2017. 
https://www.nice.org.uk/guidance/cg71 (Last accessed 2 November 2017) 
 
5. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R. Identification and management of familial 
hypercholesterolaemia: what does it mean to primary care? Brit J Gen Pract 2009; 59(567): 773-6. 
 
6. Weng SF, Kai J, Neil HA, Humphries SE, Qureshi N. Improving identification of familial 
hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia 
case ascertainment tool (FAMCAT). Atherosclerosis 2015; 238(2): 336-43. 
 
7. Talmud PJ, Shah S, Whittall R, Futema M, Howard P, Cooper JA, Harrison SC, Li K, Drenos F, Karpe F, 
Neil HA, Descamps OS, Langenberg C, Lench N, Kivimaki M, Whittaker J, Hingorani AD, Kumari M, 
Humphries SE. Use of low-density lipoprotein cholesterol gene score to distinguish patients with 
polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013 Apr 
13;381(9874):1293-301 
8. Kerr M, Pears R, Miedzybrodzka Z, Haralambos K, Cather M, Watson M, Humphries SE. Cost 
effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial 
hypercholesterolaemia services in the UK. Eur Heart J. 2017 Jun 14;38(23):1832-1839. 
9. Wilke R, Ramsey L, Johnson S, et al. The Clinical Pharmacogenomics Implementation Consortium: 
CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther2012;92(1):112-
117. doi:10.1038/clpt.2012.57. 
 
 
